Penumbraの空売り状況は、投資家がPenumbraの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Penumbra (NYSE:PEN) 株価情報, 空売り情報

Penumbra

Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are sold to hospitals and are developed for use by specialist physicians. The neurovascular product category contributes to the majority of revenue. Within the neurovascular business, the firm offers products for neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. Penumbra generates the majority of its revenue in the United States.

Movers

Trading Ideas

BIMI

DALN

FFIE

FGEN

GRPN

JTAI

LMND

MGNX

NUZE

PITA

PMEC

POWL

TBIO

TIVC

アドバンスト マイクロ デバイセズ社 (NASDAQ:AMD) の株は、予想を上回る第2四半期決算を受けて本日のプレマーケット取引で急騰している。

AMD株価上昇　決算を受けて

Penumbra Inc

Pendle - United States Dollar

Penguin Solutions, Inc. - Ordinary Shares

Penguin Solutions Inc

PENINSULA ENERGY LTD by Peninsula Energy Ltd.

Peninsula Energy Ltd

PENN Entertainment Inc

PENTAMASTER CORP BHD by PENTAMASTER CORP BHD.

PENNANT INTL GRP PLC by Pennant International Group PLC

<p>In the last three months, 11 analysts have published ratings on Penumbra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>), offering a diverse range of perspectives from bullish to bearish.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">5</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for Penumbra, presenting an average target of $237.18, a high estimate of $263.00, and a low estimate of $222.00. Surpassing the previous average price target of $210.67, the current average has increased by 12.58%.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732129249_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>The standing of Penumbra among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$250.00</td>
<td>$235.00</td>
</tr>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$235.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>David Rescott</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$248.00</td>
<td>$244.00</td>
</tr>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$225.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Jason Mills</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$235.00</td>
<td>$176.00</td>
</tr>
<tr>
<td>Ryan Zimmerman</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$234.00</td>
<td>$224.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$235.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$222.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>Mathew Blackman</td>
<td>Stifel</td>
<td>Announces</td>
<td>Buy</td>
<td>$238.00</td>
<td>-</td>
</tr>
<tr>
<td>Mike Kratky</td>
<td>Leerink Partners</td>
<td>Announces</td>
<td>Outperform</td>
<td>$263.00</td>
<td>-</td>
</tr>
<tr>
<td>Ryan Zimmerman</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$224.00</td>
<td>$187.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Penumbra. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Penumbra compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of Penumbra's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Penumbra's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/PEN/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Penumbra analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Penumbra</h2>
<p>Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are sold to hospitals and are developed for use by specialist physicians. The neurovascular product category contributes to the majority of revenue. Within the neurovascular business, the firm offers products for neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. Penumbra generates the majority of its revenue in the United States.</p>
<h3>Penumbra: Delving into Financials</h3>
<p><strong>Market Capitalization Perspectives:</strong> The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Penumbra's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of <strong>11.11%</strong>. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Penumbra's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of <strong>9.81%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Penumbra's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>2.61%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Penumbra's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>1.96%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Penumbra's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.21</strong>.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

Breaking Down Penumbra: 11 Analysts Share Their Views

<p>Piper Sandler  analyst Matt O'Brien   maintains Penumbra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>) with a Overweight and raises the price target from $235 to $250.</p>


News

Price Target

Piper Sandler Maintains Overweight on Penumbra, Raises Price Target to $250

<p><strong>Penumbra's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>) short percent of float has risen 17.58% since its last report. The company recently reported that it has <strong>2.65 million shares sold short</strong>, which is 9.63% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 8.36 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest"><strong>List of the most shorted stocks</strong></a></p>
<h3>Penumbra Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730913318_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Penumbra has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.</p>
<h3>Comparing Penumbra's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Penumbra's peer group average for short interest as a percentage of float is 4.03%, which means the company has <strong>more</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


Short Sellers

Short Ideas

How Is The Market Feeling About Penumbra?

<ul>
<li>Data presented for the first time this week at Vascular Interventional Advances (VIVA) 2024 Conference</li>
<li>Findings reinforce the clinical, health economic and cost benefits of computer assisted vacuum thrombectomy to patients and the overall health system</li>
</ul>
<p>ALAMEDA, Calif., Nov. 5, 2024 /PRNewswire/ -- <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4294875-1&amp;h=431756899&amp;u=https%3A%2F%2Fwww.penumbrainc.com%2F&amp;a=Penumbra%2C+Inc">Penumbra, Inc</a>. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>), the world's leading thrombectomy company, announced new data that demonstrate patients with intermediate-risk pulmonary embolism (PE) treated with Penumbra's computer assisted vacuum thrombectomy (CAVT&#x2122;) technology have a shorter length of hospital stay, shorter post-procedure length of stay and fewer complications when compared to other treatment options. Additionally, in-hospital mortality was low with CAVT, with no significant difference between treatment options. The late-breaking study&nbsp;was presented this week at the Vascular Interventional Advances (VIVA) 2024 Conference.</p>


Biotech

General

Penumbra To Present New Late Breaking Data Show Patients Treated With Computer Assisted Vacuum Thrombectomy Technology For Pulmonary Embolism Experience Shorter Hospital Stays And Fewer Complications Compared To Other Treatment Options At The VIVA 2024 Conference

WIIM

Penumbra shares are trading higher after the company reported better-than-expected Q3 earnings and sales.

<p>Piper Sandler  analyst Matt O'Brien   maintains Penumbra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>) with a Overweight and raises the price target from $225 to $235.</p>


Piper Sandler Maintains Overweight on Penumbra, Raises Price Target to $235

<p>Needham  analyst Mike Matson   reiterates Penumbra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>) with a Hold.</p>


Reiteration

Needham Reiterates Hold on Penumbra

<p>Baird  analyst David Rescott   maintains Penumbra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>) with a Outperform and raises the price target from $244 to $248.</p>


Baird Maintains Outperform on Penumbra, Raises Price Target to $248

<p>Penumbra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>) affirms FY2024 sales outlook from $1.18 billion-1.20 billion to $1.18 billion-1.20 billion.</p>


Guidance

Penumbra Affirms FY2024 Sales Guidance to $1.18B-1.20B VS Est. 1.19B

<p>Penumbra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>) reported quarterly earnings of $0.85 per share which beat the analyst consensus estimate of $0.69 by 23.19 percent. This is a 26.87 percent increase over earnings of $0.67 per share from the same period last year.  The company reported quarterly sales of $301.039 million which beat the analyst consensus estimate of $297.414 million by 1.22 percent.  This is a 11.11 percent increase over sales of $270.946 million the same period last year.</p>


Earnings

Earnings Beats

Penumbra Q3 2024 Adj. EPS $0.85 Beats $0.69 Estimate, Sales $301.039M Beat $297.414M Estimate

<p>In the last three months, 17 analysts have published ratings on Penumbra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>), offering a diverse range of perspectives from bullish to bearish.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $208.94, along with a high estimate of $263.00 and a low estimate of $150.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 8.84%. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1729857641_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Penumbra. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$225.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Jason Mills</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$235.00</td>
<td>$176.00</td>
</tr>
<tr>
<td>Ryan Zimmerman</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$234.00</td>
<td>$224.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$235.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$222.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>Mathew Blackman</td>
<td>Stifel</td>
<td>Announces</td>
<td>Buy</td>
<td>$238.00</td>
<td>-</td>
</tr>
<tr>
<td>Mike Kratky</td>
<td>Leerink Partners</td>
<td>Announces</td>
<td>Outperform</td>
<td>$263.00</td>
<td>-</td>
</tr>
<tr>
<td>Ryan Zimmerman</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$224.00</td>
<td>$187.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$200.00</td>
<td>$178.00</td>
</tr>
<tr>
<td>Ryan Zimmerman</td>
<td>BTIG</td>
<td>Lowers</td>
<td>Buy</td>
<td>$187.00</td>
<td>$232.00</td>
</tr>
<tr>
<td>David Rescott</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$180.00</td>
<td>$231.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$205.00</td>
<td>$289.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$200.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$200.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Jason Mills</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$176.00</td>
<td>$272.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$150.00</td>
<td>$289.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$178.00</td>
<td>$265.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Penumbra. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Penumbra compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>For valuable insights into Penumbra's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/PEN/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Penumbra analyst ratings.</strong></a></p>
<h2>All You Need to Know About Penumbra</h2>
<p>Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are sold to hospitals and are developed for use by specialist physicians. The neurovascular product category contributes to the majority of revenue. Within the neurovascular business, the firm offers products for neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. Penumbra generates the majority of its revenue in the United States.</p>
<h3>Penumbra: Delving into Financials</h3>
<p><strong>Market Capitalization:</strong> Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.</p>
<p><strong>Revenue Growth:</strong> Penumbra's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately <strong>14.49%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> Penumbra's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of <strong>-20.11%,</strong> the company may encounter challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Penumbra's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>-5.09%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> Penumbra's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>-3.87%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.2</strong>.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Key Takeaways From Penumbra Analyst Ratings

<p><strong>Penumbra's</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>) short percent of float has fallen 14.15% since its last report. The company recently reported that it has <strong>2.26 million shares sold short</strong>, which is 8.19% of all regular shares that are available for trading. Based on its trading volume, <strong>it would take traders 5.77 days to cover their short positions on average.</strong></p>
<h3>Why Short Interest Matters</h3>
<p>Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.</p>
<p>Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.</p>
<p><strong>See Also:</strong> <a href="https://www.benzinga.com/short-interest"><strong>List of the most shorted stocks</strong></a></p>
<h3>Penumbra Short Interest Graph (3 Months)</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1729265418_0.png" alt="short_fig" /></p>
<p>As you can see from the chart above the percentage of shares that are sold short for Penumbra has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.</p>
<h3>Comparing Penumbra's Short Interest Against Its Peers</h3>
<p>Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.</p>
<p>According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Penumbra's peer group average for short interest as a percentage of float is 3.98%, which means the company has <strong>more</strong> short interest than most of its peers.</p>
<p>Did you know that increasing short interest can actually be <strong>bullish</strong> for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/"><strong>This post by Benzinga Money explains how you can profit from it.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and was reviewed by an editor.</em></p>


Looking Into Penumbra's Recent Short Interest

<p>Piper Sandler  analyst Matt O'Brien   reiterates Penumbra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>) with a Overweight and raises the price target from $200 to $225.</p>


Piper Sandler Reiterates Overweight on Penumbra, Raises Price Target to $225

<p>Canaccord Genuity  analyst Jason Mills   maintains Penumbra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>) with a Buy and raises the price target from $176 to $235.</p>


Canaccord Genuity Maintains Buy on Penumbra, Raises Price Target to $235

<p>BTIG  analyst Ryan Zimmerman   maintains Penumbra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>) with a Buy and raises the price target from $224 to $234.</p>


BTIG Maintains Buy on Penumbra, Raises Price Target to $234

Penumbra shares are trading higher after the company announced it completed the enrollment in its THUNDER clinical study for patients with acute ischemic stroke. Also, Truist Securities maintained a Buy rating on the stock and raised its price target from $200 to $235.

<p>Truist Securities  analyst Richard Newitter   maintains Penumbra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>) with a Buy and raises the price target from $200 to $235.</p>


Truist Securities Maintains Buy on Penumbra, Raises Price Target to $235

<p><a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4276802-1&amp;h=1208104631&amp;u=https%3A%2F%2Fwww.penumbrainc.com%2F&amp;a=Penumbra%2C+Inc">Penumbra, Inc</a>. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>), the world's leading thrombectomy company, announced the completion of enrollment in its THUNDER clinical study for patients with acute ischemic stroke. THUNDER is evaluating the safety and efficacy of the company's latest computer assisted vacuum thrombectomy (CAVT&#x2122;) technology, Penumbra System&#x2122; with Thunderbolt&#x2122; Aspiration Tubing, for the removal of blood clots in the brain.</p>


Penumbra, Inc. Announces Completion Of THUNDER IDE Study Enrollment For Acute Ischemic Stroke

<p>16 analysts have shared their evaluations of Penumbra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $205.94, a high estimate of $263.00, and a low estimate of $150.00. This current average has decreased by 15.65% from the previous average price target of $244.14. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1728417630_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive Penumbra. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$222.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>Mathew Blackman</td>
<td>Stifel</td>
<td>Announces</td>
<td>Buy</td>
<td>$238.00</td>
<td>-</td>
</tr>
<tr>
<td>Mike Kratky</td>
<td>Leerink Partners</td>
<td>Announces</td>
<td>Outperform</td>
<td>$263.00</td>
<td>-</td>
</tr>
<tr>
<td>Ryan Zimmerman</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$224.00</td>
<td>$187.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$200.00</td>
<td>$178.00</td>
</tr>
<tr>
<td>Ryan Zimmerman</td>
<td>BTIG</td>
<td>Lowers</td>
<td>Buy</td>
<td>$187.00</td>
<td>$232.00</td>
</tr>
<tr>
<td>David Rescott</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$180.00</td>
<td>$231.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$205.00</td>
<td>$289.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$200.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$200.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Jason Mills</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$176.00</td>
<td>$272.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$150.00</td>
<td>$289.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$178.00</td>
<td>$265.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$230.00</td>
<td>$280.00</td>
</tr>
<tr>
<td>Kallum Titchmarsh</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$210.00</td>
<td>$235.00</td>
</tr>
<tr>
<td>Ryan Zimmerman</td>
<td>BTIG</td>
<td>Lowers</td>
<td>Buy</td>
<td>$232.00</td>
<td>$265.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Penumbra. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Penumbra compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for Penumbra's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>Capture valuable insights into Penumbra's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/PEN/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Penumbra analyst ratings.</strong></a></p>
<h2>All You Need to Know About Penumbra</h2>
<p>Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are sold to hospitals and are developed for use by specialist physicians. The neurovascular product category contributes to the majority of revenue. Within the neurovascular business, the firm offers products for neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. Penumbra generates the majority of its revenue in the United States.</p>
<h3>Penumbra: A Financial Overview</h3>
<p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Penumbra displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately <strong>14.49%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Penumbra's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of <strong>-20.11%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Penumbra's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>-5.09%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Penumbra's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>-3.87%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.2</strong>.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Critical Insights From Penumbra Analyst Ratings: What You Need To Know

Piper Sandler analyst Matt O'Brien raised the firm's price target on Penumbra (PEN) to $235 from $225 and keeps an Overweight rating on the shares....

Penumbra price target raised to $235 from $225 at Piper Sandler

In a report released today, Mathew Blackman from Stifel Nicolaus maintained a Buy rating on Penumbra (PEN – Research Report), with a price target o...

Stifel Nicolaus Sticks to Its Buy Rating for Penumbra (PEN)

RBC Capital raised the firm's price target on Penumbra (PEN) to $232 from $222 and keeps an Outperform rating on the shares after its Q3 earnings b...

Penumbra price target raised to $232 from $222 at RBC Capital

BTIG analyst Ryan Zimmerman maintained a Buy rating on Penumbra (PEN – Research Report) yesterday and set a price target of $232.00. The company's ...

Penumbra (PEN) Receives a Buy from BTIG

Penumbra (PEN) announced new data that demonstrate patients with intermediate-risk pulmonary embolism – PE – treated with Penumbra's computer assis...

Penumbra's CAVT technology shows benefits in pulmonary embolism

Truist Financial analyst Richard Newitter maintained a Buy rating on Penumbra (PEN – Research Report) yesterday and set a price target of $240.00. ...

Truist Financial Sticks to Their Buy Rating for Penumbra (PEN)

Wells Fargo's Growth List – META, CPAY, DXCM, and more

Fidelity Select Health Care Portfolio Q3 2024 Fund Review

Penumbra (PEN) Receives a Buy from Piper Sandler

Piper Sandler analyst Matt O'Brien raised the firm's price target on Penumbra (PEN) to $250 from $235 and keeps an Overweight rating on the shares....

Penumbra price target raised to $250 from $235 at Piper Sandler

ABBV

ABNB

ALNY

AMZN

ARGNF

ARGX

BURL

CPAY

CRWD

DXCM

EXAS

ILMN

KEYS

NVDA

ORLY

PAYC

PCVX

PLNT

PODD

SBAC

TREX

TSLA

UBER

WDAY

Press Releases

Penumbra, Inc. Announces $200 Million Share Repurchase Authorization

Penumbra, Inc. to Present at the Wells Fargo Healthcare Conference

Penumbra, Inc. to Present at the Baird Global Healthcare Conference

Penumbra Receives CE Mark for Computer Assisted Vacuum Thrombectomy Technologies - Lightning Flash™ 2.0 and Lightning Bolt™ 7 - in Europe

Penumbra, Inc. Schedules Third Quarter 2024 Earnings Release and Conference Call for October 30, 2024

Get Out the Clot Campaign Brings Together Leaders and Experts to Improve Patient Care for Venous Thromboembolism

Penumbra, Inc. Announces Completion of THUNDER IDE Study Enrollment for Acute Ischemic Stroke

Penumbra, Inc. Reports Third Quarter 2024 Financial Results

New Late Breaking Data Show Patients Treated with Penumbra's Computer Assisted Vacuum Thrombectomy Technology for Pulmonary Embolism Experience Shorter Hospital Stays and Fewer Complications Compared to Other Treatment Options

Comments

Penumbra

空売り

Penumbra (NYSE:PEN) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル